In clinical tissue specimens, VRK1, YBX1, and SOX2 were significantly overexpressed in glioma, with expression levels increasing with pathological grade, but were weakly expressed in non‐tumor tissues. This evidence concerns the gene VRK1 and central nervous system cancer.